Viral Load may not be the Key for HCV/Hepatitis C

Dr. Kottilil: During treatment with interferon-based treatments, hepatitis C viral burden levels were clinically valuable as on-treatment markers of treatment result. On the other hand, the standard-of-tend to HCV treatment has as of late developed from interferon-based regimens to brief time, all-oral, direct-acting antiviral (DAA) treatments. In this manner, it is vital that we re-assess the utility of HCV viral burdens amid DAA regimens in directing clinical choice making.

We found that Hepatitis C viral burdens on treatment and at end of treatment were not prescient of treatment achievement versus backslide with DAA treatment. As opposed to our involvement with interferon-containing regimens, low levels of quantifiable HCV RNA at end of treatment did not block treatment achievement.

Restorative Research: What ought to clinicians and patients detract from your report?

Dr. Kottilil: Clinicians and patients ought to be mindful that regular checking of Hepatitis C RNA levels amid treatment may have minimal utility in managing treatment length of time. Also, discernible or low-level quantifiable viremia at end of treatment does not imply treatment disappointment or require the augmentation of treatment. On the other hand, observing Hepatitis C viral levels on treatment for adherence on study medicines is vital.

Therapeutic Research: What proposals do you have for future examination as a consequence of this study?

Dr. Kottilil: One of the restrictions of our study was our little and particular patient populace. Hence, we prescribe further examination of the prescient capacity of Hepatitis C RNA levels for treatment result in bigger DAA trials.